ArticleFrontiers in oncology2026
Establishment and characterization of patient-derived mucinous gastric cancer organoids with faithful histopathological features and reproducible drug response patterns.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Mucinous gastric cancer (MGC) is a rare subtype of gastric cancer (GC) characterized by distinct histological features and clinical behavior. However, the lack of specific Methods: Patient-derived MGC organoids were established from paired primary tumor (MGC-T) and synchronous peritoneal metastatic nodule (MGC-ND) tissues obtained from a patient with MGC. To validate the generalizability of the findings, two additional independent MGC organoids (MGC2 and MGC3) and six non-MGC gastric cancer organoids were established in parallel under identical three-dimensional culture conditions. Histological and immunohistochemical analyses were performed to evaluate the fidelity of organoid recapitulation of parental tumor features. High-throughput drug sensitivity screening was conducted using a panel of 11 chemotherapeutic agents. Furthermore, organoid-based drug responses were correlated with the clinical outcomes of eight patients who received oxaliplatin-based adjuvant chemotherapy. Results: All MGC organoids faithfully maintained the histological architecture, mucus secretion capability, and biomarker profiles of the parental tumors over serial passages. High-throughput drug sensitivity screening revealed consistent resistance to 5-fluorouracil and oxaliplatin, and marked sensitivity to taxane-based agents, across the MGC panel. Preliminary clinical correlation in eight patients showed 87.5% concordance between organoid-based predictions and actual chemotherapy outcomes. Conclusion: We established and characterized patient-derived MGC organoids from three patients, demonstrating faithful histological and molecular preservation, dynamic mucus secretion, and reproducible drug sensitivity pattern. Preliminary clinical correlation in a small cohort showed promising concordance. These proof-of-concept findings establish a platform for future precision oncology research in this rare gastric cancer subtype, pending larger prospective validation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.